Page 5 - Aduhelm News Today

For those now grappling with Alzheimers, lecanemab holds out the promise of slowing the diseases progress. Are the modest benefits worth the risks?

Death rates about the same in both groups. but its going to end up being a discussion with the doctor, the patient, and the family if this gets approved and to really weigh those risk benefits. it may not be applicable to people on blood thinners. >> so, whats the process now? >> so, i mean, at this point, i think if it gets approved, so, the drug company is hoping that it will get accelerated approval in january and they will apply for full approval by april. then the big question is what happe...

US regulators approved CSL Behring’s haemophilia B gene therapy, a one-off infusion that frees patients from regular treatments but costs $3.5m a dose, making it the most expensive medicine in the world.

How to balance patient’s needs with their safety.

The answer is tied to Medicare and how seniors pay for it.

Nebraska officials are predicting a controversial new Alzheimers drug could drive up state Medicaid costs by more than $16 million annually.

Biogen’s Alzheimer’s drug results are breathing new life into a class of anti-amyloid drugs that had been partially written off

Eisai is aiming for full approval and commercialization of the drug in the United States, Europe, and Japan by the end of 2023, CEO Haruo Naito told reporters in Tokyo. The company said results from the 1,800-patient trial prove the longstanding theory that removal of sticky deposits of a protein called amyloid beta from the brains of people with early Alzheimer's can delay advance of the debilitating disease.

Biogen and Eisai reported the finding from a large late-stage clinical trial of lecanemab, a drug they are developing.

President Joe Biden on Tuesday touted a decline in costs for tens of millions of Americans covered by the ...